Understanding the Molecular Determinants Driving the Immunological Specificity of the Protective Pilus 2a Backbone Protein of Group B Streptococcus

PLoS Computational Biology

Volumn 9, Issue 6, 2013, Pages

  Nuccitelli, Annalisa ^a,e   Rinaudo, C Daniela ^a   Brogioni, Barbara ^a   Cozzi, Roberta ^a   Ferrer Navarro, Mario ^b   Yero, Daniel ^b   Telford, John L ^a   Grandi, Guido ^a   Daura, Xavier ^b,c   Zacharias, Martin ^d   Maione, Domenico ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e Babraham Research Campus   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL STRUCTURE; EPITOPES;

ALLELIC VARIANTS; BACTERIAL SURFACES; BINDING INTERFACE; GROUP B STREPTOCOCCUS; LINEAR EPITOPES; MOLECULAR DETERMINANTS; OPSONOPHAGOCYTOSIS; PILI STRUCTURES; PROTEIN VARIANTS; SINGLE RESIDUE;

MONOCLONAL ANTIBODIES;

PILUS 2A BACKBONE PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BACTERIUM PILUS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG SPECIFICITY; DRUG TARGETING; EPITOPE MAPPING; MOLECULAR DOCKING; MOUSE; MUTAGENESIS; NONHUMAN; OPSONIZATION; PARTICLE SIZE; PHAGOCYTOSIS; STREPTOCOCCUS AGALACTIAE; SURFACE CHARGE;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS SP. 'GROUP B';

EID: 84879540395     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003115     Document Type: Article

References (39)

1. Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, et al. (2010) Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18: 1116-1126.
2. Ofek G, Guenaga FJ, Schief WR, Skinner J, Baker D, et al. (2010) Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A 107: 17880-17887.
3. Greenspan NS, Cooper LJ, (1995) Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions. Immunol Today 16: 226-230.
4. Padlan EA, Abergel C, Tipper JP, (1995) Identification of specificity-determining residues in antibodies. FASEB J 9: 133-139.
5. Pauling L, Delbruck M, (1940) The Nature of the Intermolecular Forces Operative in Biological Processes. Science 92: 77-79.
6. Shil P, Chavan S, Cherian S, (2011) Molecular basis of antigenic drift in Influenza A/H3N2 strains (1968-2007) in the light of antigenantibody interactions. Bioinformation 6: 266-270.
7. Johri AK, Paoletti LC, Glaser P, Dua M, Sharma PK, et al. (2006) Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 4: 932-942.
8. Lauer P, Rinaudo CD, Soriani M, Margarit I, Maione D, et al. (2005) Genome analysis reveals pili in Group B Streptococcus. Science 309: 105.
9. Rosini R, Rinaudo CD, Soriani M, Lauer P, Mora M, et al. (2006) Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol 61: 126-141.
10. Dramsi S, Caliot E, Bonne I, Guadagnini S, Prevost MC, et al. (2006) Assembly and role of pili in group B streptococci. Mol Microbiol 60: 1401-1413.
11. Necchi F, Nardi-Dei V, Biagini M, Assfalg M, Nuccitelli A, et al. (2011) Sortase A substrate specificity in GBS pilus 2a cell wall anchoring. PLoS One 6: e25300.
12. Nobbs AH, Rosini R, Rinaudo CD, Maione D, Grandi G, et al. (2008) Sortase A utilizes an ancillary protein anchor for efficient cell wall anchoring of pili in Streptococcus agalactiae. Infect Immun 76: 3550-3560.
13. Margarit I, Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, et al. (2009) Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 199: 108-115.
14. Nuccitelli A, Cozzi R, Gourlay LJ, Donnarumma D, Necchi F, et al. (2011) Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci U S A 108: 10278-10283.
15. Sali A, Potterton L, Yuan F, van Vlijmen H, Karplus M, (1995) Evaluation of comparative protein modeling by MODELLER. Proteins 23: 318-326.
16. Zacharias M, (2005) ATTRACT: protein-protein docking in CAPRI using a reduced protein model. Proteins 60: 252-256.
17. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, et al. (2005) GROMACS: fast, flexible, and free. J Comput Chem 26: 1701-1718.
18. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD, (2006) GARD: a genetic algorithm for recombination detection. Bioinformatics 22: 3096-3098.
19. Kosakovsky Pond SL, Frost SD, Muse SV, (2005) HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676-679.
20. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, et al. (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309: 148-150.
21. Lancefield RC, McCarty M, Everly WN, (1975) Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med 142: 165-179.
22. Lefebure T, Stanhope MJ, (2007) Evolution of the core and pan-genome of Streptococcus: positive selection, recombination, and genome composition. Genome Biol 8: R71.
23. Li Y, Lipschultz CA, Mohan S, Smith-Gill SJ, (2001) Mutations of an epitope hot-spot residue alter rate limiting steps of antigen-antibody protein-protein associations. Biochemistry 40: 2011-2022.
24. Peter JF, Tomer KB, (2001) A general strategy for epitope mapping by direct MALDI-TOF mass spectrometry using secondary antibodies and cross-linking. Anal Chem 73: 4012-4019.
25. Koehler C, Carlier L, Veggi D, Balducci E, Di Marcello F, et al. (2011) Structural and biochemical characterization of NarE, an iron-containing ADP-ribosyltransferase from Neisseria meningitidis. J Biol Chem 286: 14842-14851.
26. Soriani M, Petit P, Grifantini R, Petracca R, Gancitano G, et al. (2010) Exploiting antigenic diversity for vaccine design: the chlamydia ArtJ paradigm. J Biol Chem 285: 30126-30138.
27. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
28. Delport W, Poon AF, Frost SD, Kosakovsky Pond SL, (2010) Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics 26: 2455-2457.
29. Kosakovsky Pond SL, Frost SD, (2005) Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol 22: 1208-1222.
30. Fiser A, Sali A, (2003) Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 374: 461-491.
31. Zacharias M, (2003) Protein-protein docking with a reduced protein model accounting for side-chain flexibility. Protein Sci 12: 1271-1282.
32. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, et al. (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78: 1950-1958.
33. Jorgensen W, (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79.
34. Hoover WG, Ciccotti G, Paolini G, Massobrio C, (1985) Lennard-Jones triple-point conductivity via weak external fields: Additional calculations. Phys Rev A 32: 3765-3767.
35. Nose S, Klein ML, (1986) Constant-temperature-constant-pressure molecular-dynamics calculations for molecular solids: Application to solid nitrogen at high pressure. Phys Rev B Condens Matter 33: 339-342.
36. Parrinello MRA, (1981) Polymorphic transitions in single crystals: A new molecular dynamics method. J Appl Phys 52: 7182-7190.
37. Nose S, Klein ML, (1983) Constant pressure molecular dynamics for molecular systems. Mol Phys 50: 1055-1076.
38. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38, 33-38, 27-38.
39. Kabat EA, Wu TT, (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147: 1709-1719.